FIELD: medicine; oncology.
SUBSTANCE: present invention relates to the field of medicine, namely to oncology; it is intended for the treatment of BRAF-associated cancer, while it includes injection to a patient who needs it of a combination therapy that independently includes therapeutically effective amounts of: (a) BRAF inhibitor, which is methyl-N-[(2S)-1-({4-[3-(5-chloro-2fluoro-3-methanesulfonamidophenyl)-1-(propane-2-yl)-1H-pyrazole-4-yl]pyrimidine-2-yl}amino)propane-2-yl]carbamate (COMPOUND A), (b) MEK inhibitor (COMPOUND B), which is (2-hydroxyethoxy)amide of 6-(4-bromine-2-fluorphenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid, and (c) an antibody against EGFR (COMPOUND C), which is cetuximab.
EFFECT: effective and long-term treatment of cancer using a combination therapy method.
30 cl, 14 tbl, 8 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| PROPOSED 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | 2022 |
|
RU2826000C1 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| METHODS AND COMBINED THERAPEUTIC PRODUCT FOR THE TREATMENT OF BILE DUCTS CANCER | 2019 |
|
RU2793543C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
